Page 1251 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1237

131
Protein binding Pulmonary hypertension Radioactive iodine ( I, RAI), 695–696,
albumin concentration in, 53 case study of, 321, 338 701t
capacity-limited, 53 eicosanoids for, 335 Radiofrequency catheter ablation, 246b
factors in, 53 nitric oxide for, 344 Raloxifene
plasma, 53, 53b preparations available, 318t description of, 737f, 738
Protein C, 611 treatment of, 313b osteoporosis treated with, 780b, 787,
Protein S, 611 Purine analogs, 1109–1110, 1116t 790t
Protein tyrosine kinase, 27 Purine antagonists Raltegravir, 872t, 884
Prothrombin complex concentrates, 616 cladribine, 958t, 961 Ramelteon, 287b, 382, 384b, 394t. See also
Prothrombin deficiency, 622t fludarabine, 958t, 961 Melatonin receptor, agonists of
Prothrombin time (PT), 615 6-thiopurines, 958t, 960–961, 961f Ramipril, hypertension treated with, 187
Proton-pump inhibitors (PPIs), 1091–1095 Purines, in CNS, 380 Ramucirumab, 968, 993
adverse effects of, 1094–1095 “Purple glove syndrome,” 418 Randomization, 15b
chemistry and pharmacokinetics of, Pyrantel pamoate, 939t, 945–946 Randomized controlled trails (RCTs), 15b
1091–1093, 1092f, 1092t Pyrazinamide, 842, 843t, 846, 851t Ranibizumab, 995
clinical uses of, 1093–1094 Pyrethrum, 1012, 1013f Ranitidine, 1089–1091. See also
drug interactions of, 1095 Pyridostigmine, 122t H 2 -receptor antagonists
OTC, 1122t myasthenia gravis treated with, 119 RANK ligand (RANKL)
pharmacodynamics of, 1093 neuromuscular blockade reversal using, description of, 775
preparations available, 1117t 484 inhibitors of, for hyperparathyroidism,
Prototype drugs, 10 Pyrimethamine, 919f, 926 790t
Protriptyline, 546t Pyrimidine analog, 855f, 856, 861t Ranolazine
Proximal convoluted tubule (PCT), Pyrimidine synthesis inhibitors, 988–989 angina pectoris treated with, 207, 210t,
254–256, 255f Pyronaridine, 928 211t
Prucalopride, 1100 arrhythmia treated with, 247
Prussian blue, 1033 Q Rapamycin, 1058
Pseudocholinesterase, 69, 132. See Qinghaosu, 922–923 Rare disease treatment, 18
Butyrylcholinesterase (BCHE) Quantal dose–effect curves, 37, 37f Rasagiline, 500, 508t
Pseudoephedrine, 150 Quantity, of exposure, 1005 Rasburicase, 80t, 82
Pseudovitamin D deficiency rickets, 788 Quaternary amine, 9 Rate of administration, 51
Psilocybin Quaternary ammonium compounds, Rate of elimination, 45
description of, 577t 899–900 Rational drug design, 4
G io protein-coupled receptor activation Quazepam, 393t. See also Benzodiazepines Rational prescribing, 1148–1149
by, 577t, 582–583 Quetiapine, 514f, 515, 520t, 529t Rattlesnake envenomation management,
Psoralens, 1076 “Quicksilver,” 1027 1045
Psoriasis Quinagolide, 679 Rattlesnake hyperimmune globulin, 991
acitretin for, 1078 Quinapril, 187 Raxibacumab, 995
alefacept for, 1079 Quinestrol, 723f. See also Estrogen(s) Reactive oxygen species (ROS), 63, 65
calcipotriene and calcitriol for, Quinidine Reactivity, drug, 3–4. See also specific drugs
1078–1079 arrhythmia treated with, 239t, 240, “Rebound rhinitis,” 1128
fumaric acid esters for, 1079 240t, 250t Reboxetine, 151
tazarotene for, 1078 drug interactions of, 1171t Receptor, 20–36. See also specific drugs and
TNF inhibitors for, 1079 malaria treated with, 923–924 receptors
ustekinumab for, 1079 Quinine, 919f, 920t, 923–924 in addiction, 576
Psychosis Quinolone antibiotics, 1171t–1172t as agonist and antagonist mediators,
drugs for, 511–524, 528t–529t Quinupristin-dalfopristin, 822, 20–21
nature of, 512 824t, 825t alterations in number or function of, 38
Psyllium, 1098 autonomic, 98–99, 99t
Pteroylglutamic acid, 606t. See also Folic acid R definition of, 3, 20
p-Tertiary amylphenol, 899 Rabbit syndrome, 506 drug concentration and response, 20,
PTSD, Posttraumatic stress disorder, 544 Rabeprazole, 1091–1095. See also Proton- 21–26
PU-14, 269 pump inhibitors (PPIs) drug concentration reaching, 38
Pulmonary disease, 72. See also specific Rabies drug development and, 35–36
disease immune globulin intravenous for, 1180t on drug dose and clinical response,
Pulmonary edema, acute, 563 vaccine for, 1177t 36–40. See also Dose, clinical
Pulmonary embolism Radiation, nausea and vomiting after, response and
heparin for, 608, 625 1104–1105, 1116t, 1117t in drug selectivity, 20
thrombolytics for, 619 Radical cure, 917 “gene-active,” 27